Optimizing care for younger women with hormone receptor‐positive, HER2‐negative metastatic breast cancer

Boer, Richard de; Hui, Rina; Lim, Elgene; Yeo, Belinda; Zdenkowski, Nicholas

doi:10.1111/ajco.13461

Cited by 4 publications

(4 citation statements)

References 74 publications

(322 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, following PARSIFAL data, letrozole remains the preferred endocrine therapy for patients without endocrine resistance [27]. Younger age is associated with more aggressive tumor biology, higher grade, and more advanced disease, and these patients tend to have a worse prognosis [28,29]. In the premenopausal population of our study, almost half (48%) of the patients received ribociclib.…”

Section: Discussionmentioning

confidence: 65%

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

Cejuela

Gil-Torralvo

Castilla

et al. 2023

IJMS

View full text Add to dashboard Cite

By the end of 2020, there were more than 8 million women alive who had received a breast cancer diagnosis in the previous 5 years, making it the most prevalent neoplasia in the world. About 70% of breast-cancer cases present positivity for estrogen and/or progesterone receptors and a lack of HER-2 overexpression. Endocrine therapy has traditionally been the standard of care for ER-positive and HER-2-negative metastatic breast cancer. In the last 8 years, the advent of CDK4/6 inhibitors has shown that adding them to endocrine therapy doubles PFS. As a result, this combination has become the gold standard in this setting. Three CDK4/6 inhibitors have been approved by the EMA and the FDA: abemaciclib, palbociclib, and ribociclib. They all have the same indications, and it is at each physician’s discretion to choose one or the other. The aim of our study was to perform a comparative efficacy analysis of the three CDK4/6i using real-world data. We selected patients diagnosed with endocrine-receptor-positive and HER2-negative breast cancer who were treated with all three CDK4/6i as first-line therapy at a reference center. After 42 months of retrospective follow up, abemaciclib was associated with a significant benefit in terms of progression-free survival in endocrine-resistant patients and in the population without visceral involvement. In our real-world cohort, we found no other statistically significant differences among the three CDK4/6 inhibitors.

show abstract

Section: Discussionmentioning

confidence: 65%

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

Cejuela

Gil-Torralvo

Castilla

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…6,10,[12][13][14][15] A number of ongoing and completed trials specifically, however, have included pre-/perimenopausal women (who also received treatment to suppress ovarian function, in accordance with current treatment guidelines pertaining to hormonal therapy in pre/perimenopausal women). 6,12,[16][17][18] In MONALEESA-7, which included only pre-/perimenopausal women, the addition of ribociclib to a nonsteroidal AI or tamoxifen (plus goserelin) improved PFS (hazard ratio = 0.55, 95% CI = 0.44-0.69, p < 0.0001) to a median of 23.8 months for the combination of ribociclib plus ET compared with a median of 13.0 months for ET alone, as well as OS (hazard ratio = 0.76, 95% CI = 0.61-0.96) with median OS 58.7 months versus 48.0 months, respectively. 17,18 Although the addition of targeted agents (such as CDK4/6 inhibitors) can successfully prolong endocrine sensitivity and thus delay chemotherapy and its associated toxicity in patients with MBC, resistance to ET will ultimately occur.…”

Section: Introductionmentioning

confidence: 99%

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclibversusletrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Bardia

Cortés²,

Hurvitz

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: For estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combination with a cyclin-dependent kinase 4/6 inhibitor. When resistance occurs, often related to the occurrence of ESR1 mutations, selective estrogen receptor modulators or degraders (SERDs) may be used, alone or in combination regimens. Amcenestrant (SAR439859), an optimized oral SERD, has shown clinical antitumor activity in combination with palbociclib in patients with ER+/HER2– ABC and, as monotherapy, in patients with and without ESR1 mutations. Here, we describe the study design of AMEERA-5, an ongoing, prospective, phase 3, randomized, double-blind, multinational study comparing the efficacy and safety of amcenestrant plus palbociclib versus letrozole plus palbociclib in patients with advanced (locoregional recurrent or metastatic) ER+/HER2– breast cancer. Methods: Patients are pre-/postmenopausal women and men with no prior systemic therapy for ABC. The planned enrollment is 1066 patients. Patients are randomized 1:1 to either amcenestrant 200 mg plus palbociclib 125 mg or letrozole 2.5 mg plus palbociclib 125 mg. Amcenestrant, letrozole, and their matching placebos are taken once daily continuously; palbociclib is taken once daily for 21 days, followed by 7 days off-treatment for a 28-day cycle. Treatment continues until disease progression, unacceptable toxicity, or decision to stop treatment. Pre-/perimenopausal women and men receive goserelin subcutaneously. Randomization is stratified by de novo metastatic disease, menopausal status, and visceral metastases. The primary endpoint is progression-free survival. The key secondary endpoint is overall survival; others are safety, pharmacokinetics, and quality of life. Conclusions: AMEERA-5 is evaluating the efficacy and safety of amcenestrant in combination with palbociclib as first-line therapy in pre-/postmenopausal women and men with ER+/HER2– ABC. ClinicalTrials Identifier: NCT04478266.

show abstract

“…Breast cancer in young women is likely to be fast-growing and high-grade [ 1 , 2 , 3 ]. As a result, treatment can include a combination of surgery, chemotherapy, radiation, and hormone therapy.…”

Section: Introductionmentioning

confidence: 99%

Gender Socialization as a Predictor of Psychosocial Well-Being in Young Women with Breast Cancer

Trachtenberg¹,

Esplen

Toner

et al. 2022

Current Oncology

View full text Add to dashboard Cite

This study aimed to explore the relationship between gender socialization and psychosocial well-being among young women diagnosed with and treated for breast cancer. A total of 113 women between the ages of 18–49 completed a one-time questionnaire package. Four key measures of gender socialization were included: Gender Role Socialization Scale (GRSS), Objectified Body Consciousness Scale (OBCS), Mental Freedom Scale (MFS), and Silencing the Self Scale (SSS). Two measures of psychosocial well-being were included: Functional Assessment of Cancer Therapy-Breast (FACT-B) and Experience of Embodiment Scale (EES). Correlational and regression analyses were conducted to assess the relationship between gender socialization variables and well-being. In multiple regression models, GRSS and MFS added significant increments to the prediction of variance of the FACT-B (R2 = 23.0%). In contrast, the OBCS and MFS added significant increments to the prediction of variance of the EES (R2 = 47.0%). Findings suggested that women with greater endorsements to proscribed gender socialization were associated with poor well-being scores. Women who endorsed a critical stance, resisting traditional gender-role expectations, objectification pressures, and other social discourses, were associated with greater well-being scores. Future studies are needed to examine the impact of gender socialization on the well-being of young people with breast cancer.

show abstract

Optimizing care for younger women with hormone receptor‐positive, HER2‐negative metastatic breast cancer

Cited by 4 publications

References 74 publications

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclibversusletrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Gender Socialization as a Predictor of Psychosocial Well-Being in Young Women with Breast Cancer

Contact Info

Product

Resources

About